Karmokar PF, Moniri NH (December 2022). "Oncogenic signaling of the free-fatty acid receptors FFA1 and FFA4 in human breast carcinoma cells". Biochemical Pharmacology. 206: 115328. doi:10.1016/j.bcp.2022.115328. PMID36309079. S2CID253174629.
Duah M, Zhang K, Liang Y, Ayarick VA, Xu K, Pan B (February 2023). "Immune regulation of poly unsaturated fatty acids and free fatty acid receptor 4". The Journal of Nutritional Biochemistry. 112: 109222. doi:10.1016/j.jnutbio.2022.109222. PMID36402250. S2CID253652038.
Governa P, Caroleo MC, Carullo G, Aiello F, Cione E, Manetti F (June 2021). "FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity". Bioorganic & Medicinal Chemistry Letters. 41: 127969. doi:10.1016/j.bmcl.2021.127969. PMID33771587. S2CID232375863.
Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CR, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P (May 2018). "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84". The American Journal of Pathology. 188 (5): 1132–1148. doi:10.1016/j.ajpath.2018.01.009. PMID29454750.
Li H, Liu Y, Xiao J, Huang J, Zhang Y (May 2023). "Preclinical pharmacokinetics and metabolism study of SCO-267, a GPR40 full agonist, in beagle dogs using ultra-high performance liquid chromatography coupled to tandem mass spectrometry". Biomedical Chromatography. 37 (9): e5685. doi:10.1002/bmc.5685. PMID37189222. S2CID258716947.
Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, Sharma R, Schmitt M, Wang Y, Liu J, Liu J, Medina JC, Reagan JD, Luo J, Tonn G, Zhang J, Lu JY, Chen M, Lopez E, Nguyen K, Yang L, Tang L, Tian H, Shuttleworth SJ, Lin DC (January 2012). "AMG 837: a potent, orally bioavailable GPR40 agonist". Bioorganic & Medicinal Chemistry Letters. 22 (2): 1267–70. doi:10.1016/j.bmcl.2011.10.118. PMID22217876.
Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR (February 2018). "Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus". Journal of Medicinal Chemistry. 61 (3): 934–945. doi:10.1021/acs.jmedchem.7b01411. PMID29236497.
Teng D, Chen J, Li D, Wu Z, Li W, Tang Y, Liu G (June 2020). "Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators". Journal of Chemical Information and Modeling. 60 (6): 3214–3230. doi:10.1021/acs.jcim.0c00030. PMID32338509. S2CID216557375.
Zhang X, Yan G, Li Y, Zhu W, Wang H (November 2010). "DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats". Biomedicine & Pharmacotherapy. 64 (9): 647–51. doi:10.1016/j.biopha.2010.06.008. PMID20888730.
Wang B, Cai Z, Yao H, Jiao S, Chen S, Yang Z, Huang W, Ren Q, Cao Z, Chen Y, Zhang L, Li Z (January 2023). "Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes". European Journal of Medicinal Chemistry. 245 (Pt 1): 114883. doi:10.1016/j.ejmech.2022.114883. PMID36343410. S2CID253334545.
Ichimura A, Hirasawa A, Hara T, Tsujimoto G (September 2009). "Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis". Prostaglandins & Other Lipid Mediators. 89 (3–4): 82–8. doi:10.1016/j.prostaglandins.2009.05.003. PMID19460454.
Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K (October 2011). "TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 228–37. doi:10.1124/jpet.111.183772. PMID21752941. S2CID14605410.
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (September 2016). "Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study". Diabetes, Obesity & Metabolism. 18 (9): 925–9. doi:10.1111/dom.12693. PMID27178047. S2CID21501077.
Iwasaki N, Sakamoto K, Kitajima S, Maruyama Y, Kuroda M (May 2021). "GPR120 agonists enhance the fatty orosensation when added to fat-containing system, but do not evoke it by themselves in humans". Physiology & Behavior. 234: 113383. doi:10.1016/j.physbeh.2021.113383. PMID33676959. S2CID232116893.
Aizawa F, Nishinaka T, Yamashita T, Nakamoto K, Kurihara T, Hirasawa A, Kasuya F, Miyata A, Tokuyama S (December 2016). "GPR40/FFAR1 deficient mice increase noradrenaline levels in the brain and exhibit abnormal behavior". Journal of Pharmacological Sciences. 132 (4): 249–254. doi:10.1016/j.jphs.2016.09.007. hdl:2433/218924. PMID27979701.
Alavi MS, Shamsizadeh A, Azhdari-Zarmehri H, Roohbakhsh A (February 2018). "Orphan G protein-coupled receptors: The role in CNS disorders". Biomedicine & Pharmacotherapy. 98: 222–232. doi:10.1016/j.biopha.2017.12.056. PMID29268243.
Sona C, Kumar A, Dogra S, Kumar BA, Umrao D, Yadav PN (October 2018). "Docosahexaenoic acid modulates brain-derived neurotrophic factor via GPR40 in the brain and alleviates diabesity-associated learning and memory deficits in mice". Neurobiology of Disease. 118: 94–107. doi:10.1016/j.nbd.2018.07.002. PMID29981843. S2CID51601327.
Gong Y, Li Y, Liu X, He L (October 2021). "GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Aβ1-42 induced mouse model of Alzheimer's disease". European Journal of Pharmacology. 909: 174362. doi:10.1016/j.ejphar.2021.174362. PMID34297968.
Khan MZ, Zhuang X, He L (May 2016). "GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model". Neurobiology of Learning and Memory. 131: 46–55. doi:10.1016/j.nlm.2016.03.006. PMID26976092. S2CID46877767.
Liu C, Cheng ZY, Xia QP, Hu YH, Wang C, He L (August 2021). "GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces β-amyloid production in APPswe/PS1dE9 mice". Psychopharmacology. 238 (8): 2133–2146. doi:10.1007/s00213-021-05837-4. PMID34173034. S2CID235648319.
Chen J, Li Q, Zhu J, Yuan Z, Wang T, Song J (December 2021). "GPR40 Agonist Ameliorate Pathological Neuroinflammation of Alzheimer's Disease via the Modulation of Gut Microbiota and Immune System, a Mini-Review". Neurotoxicity Research. 39 (6): 2175–2185. doi:10.1007/s12640-021-00408-z. PMID34505972. S2CID237472180.
Kita T, Kadochi Y, Takahashi K, Fukushima K, Yamasaki E, Uemoto T, Hirane M, Fukushima N, Honoki K, Tsujiuchi T (March 2016). "Diverse effects of G-protein-coupled free fatty acid receptors on the regulation of cellular functions in lung cancer cells". Experimental Cell Research. 342 (2): 193–9. doi:10.1016/j.yexcr.2016.03.008. PMID26968637.
Fukushima K, Yamasaki E, Ishii S, Tomimatsu A, Takahashi K, Hirane M, Fukushima N, Honoki K, Tsujiuchi T (September 2015). "Different roles of GPR120 and GPR40 in the acquisition of malignant properties in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 465 (3): 512–5. doi:10.1016/j.bbrc.2015.08.050. PMID26282200.
Takahashi K, Fukushima K, Onishi Y, Node Y, Inui K, Fukushima N, Honoki K, Tsujiuchi T (March 2017). "Different effects of G-protein-coupled receptor 120 (GPR120) and GPR40 on cell motile activity of highly migratory osteosarcoma cells". Biochemical and Biophysical Research Communications. 484 (3): 675–680. doi:10.1016/j.bbrc.2017.01.175. PMID28159555.
Zhang M, Qiu S (March 2019). "Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-κB signaling pathway". Anti-Cancer Drugs. 30 (3): 260–270. doi:10.1097/CAD.0000000000000716. PMID30520776. S2CID54568134.
Prado TP, Jara CP, Dias Bóbbo VC, Carraro RS, Sidarta-Oliveira D, de Mendonça GR, Velloso LA, Araújo EP (July 2023). "A Free Fatty Acid Synthetic Agonist Accelerates Wound Healing and Improves Scar Quality in Mice". Biological Research for Nursing. 25 (3): 353–366. doi:10.1177/10998004221142331. PMID36444640. S2CID254067558.
Karmokar PF, Moniri NH (December 2022). "Oncogenic signaling of the free-fatty acid receptors FFA1 and FFA4 in human breast carcinoma cells". Biochemical Pharmacology. 206: 115328. doi:10.1016/j.bcp.2022.115328. PMID36309079. S2CID253174629.
Duah M, Zhang K, Liang Y, Ayarick VA, Xu K, Pan B (February 2023). "Immune regulation of poly unsaturated fatty acids and free fatty acid receptor 4". The Journal of Nutritional Biochemistry. 112: 109222. doi:10.1016/j.jnutbio.2022.109222. PMID36402250. S2CID253652038.
Governa P, Caroleo MC, Carullo G, Aiello F, Cione E, Manetti F (June 2021). "FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity". Bioorganic & Medicinal Chemistry Letters. 41: 127969. doi:10.1016/j.bmcl.2021.127969. PMID33771587. S2CID232375863.
Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CR, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P (May 2018). "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84". The American Journal of Pathology. 188 (5): 1132–1148. doi:10.1016/j.ajpath.2018.01.009. PMID29454750.
Li H, Liu Y, Xiao J, Huang J, Zhang Y (May 2023). "Preclinical pharmacokinetics and metabolism study of SCO-267, a GPR40 full agonist, in beagle dogs using ultra-high performance liquid chromatography coupled to tandem mass spectrometry". Biomedical Chromatography. 37 (9): e5685. doi:10.1002/bmc.5685. PMID37189222. S2CID258716947.
Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, Sharma R, Schmitt M, Wang Y, Liu J, Liu J, Medina JC, Reagan JD, Luo J, Tonn G, Zhang J, Lu JY, Chen M, Lopez E, Nguyen K, Yang L, Tang L, Tian H, Shuttleworth SJ, Lin DC (January 2012). "AMG 837: a potent, orally bioavailable GPR40 agonist". Bioorganic & Medicinal Chemistry Letters. 22 (2): 1267–70. doi:10.1016/j.bmcl.2011.10.118. PMID22217876.
Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR (February 2018). "Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus". Journal of Medicinal Chemistry. 61 (3): 934–945. doi:10.1021/acs.jmedchem.7b01411. PMID29236497.
Teng D, Chen J, Li D, Wu Z, Li W, Tang Y, Liu G (June 2020). "Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators". Journal of Chemical Information and Modeling. 60 (6): 3214–3230. doi:10.1021/acs.jcim.0c00030. PMID32338509. S2CID216557375.
Zhang X, Yan G, Li Y, Zhu W, Wang H (November 2010). "DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats". Biomedicine & Pharmacotherapy. 64 (9): 647–51. doi:10.1016/j.biopha.2010.06.008. PMID20888730.
Wang B, Cai Z, Yao H, Jiao S, Chen S, Yang Z, Huang W, Ren Q, Cao Z, Chen Y, Zhang L, Li Z (January 2023). "Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes". European Journal of Medicinal Chemistry. 245 (Pt 1): 114883. doi:10.1016/j.ejmech.2022.114883. PMID36343410. S2CID253334545.
Ichimura A, Hirasawa A, Hara T, Tsujimoto G (September 2009). "Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis". Prostaglandins & Other Lipid Mediators. 89 (3–4): 82–8. doi:10.1016/j.prostaglandins.2009.05.003. PMID19460454.
Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K (October 2011). "TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 228–37. doi:10.1124/jpet.111.183772. PMID21752941. S2CID14605410.
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (September 2016). "Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study". Diabetes, Obesity & Metabolism. 18 (9): 925–9. doi:10.1111/dom.12693. PMID27178047. S2CID21501077.
Iwasaki N, Sakamoto K, Kitajima S, Maruyama Y, Kuroda M (May 2021). "GPR120 agonists enhance the fatty orosensation when added to fat-containing system, but do not evoke it by themselves in humans". Physiology & Behavior. 234: 113383. doi:10.1016/j.physbeh.2021.113383. PMID33676959. S2CID232116893.
Aizawa F, Nishinaka T, Yamashita T, Nakamoto K, Kurihara T, Hirasawa A, Kasuya F, Miyata A, Tokuyama S (December 2016). "GPR40/FFAR1 deficient mice increase noradrenaline levels in the brain and exhibit abnormal behavior". Journal of Pharmacological Sciences. 132 (4): 249–254. doi:10.1016/j.jphs.2016.09.007. hdl:2433/218924. PMID27979701.
Alavi MS, Shamsizadeh A, Azhdari-Zarmehri H, Roohbakhsh A (February 2018). "Orphan G protein-coupled receptors: The role in CNS disorders". Biomedicine & Pharmacotherapy. 98: 222–232. doi:10.1016/j.biopha.2017.12.056. PMID29268243.
Sona C, Kumar A, Dogra S, Kumar BA, Umrao D, Yadav PN (October 2018). "Docosahexaenoic acid modulates brain-derived neurotrophic factor via GPR40 in the brain and alleviates diabesity-associated learning and memory deficits in mice". Neurobiology of Disease. 118: 94–107. doi:10.1016/j.nbd.2018.07.002. PMID29981843. S2CID51601327.
Gong Y, Li Y, Liu X, He L (October 2021). "GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Aβ1-42 induced mouse model of Alzheimer's disease". European Journal of Pharmacology. 909: 174362. doi:10.1016/j.ejphar.2021.174362. PMID34297968.
Khan MZ, Zhuang X, He L (May 2016). "GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model". Neurobiology of Learning and Memory. 131: 46–55. doi:10.1016/j.nlm.2016.03.006. PMID26976092. S2CID46877767.
Liu C, Cheng ZY, Xia QP, Hu YH, Wang C, He L (August 2021). "GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces β-amyloid production in APPswe/PS1dE9 mice". Psychopharmacology. 238 (8): 2133–2146. doi:10.1007/s00213-021-05837-4. PMID34173034. S2CID235648319.
Chen J, Li Q, Zhu J, Yuan Z, Wang T, Song J (December 2021). "GPR40 Agonist Ameliorate Pathological Neuroinflammation of Alzheimer's Disease via the Modulation of Gut Microbiota and Immune System, a Mini-Review". Neurotoxicity Research. 39 (6): 2175–2185. doi:10.1007/s12640-021-00408-z. PMID34505972. S2CID237472180.
Kita T, Kadochi Y, Takahashi K, Fukushima K, Yamasaki E, Uemoto T, Hirane M, Fukushima N, Honoki K, Tsujiuchi T (March 2016). "Diverse effects of G-protein-coupled free fatty acid receptors on the regulation of cellular functions in lung cancer cells". Experimental Cell Research. 342 (2): 193–9. doi:10.1016/j.yexcr.2016.03.008. PMID26968637.
Fukushima K, Yamasaki E, Ishii S, Tomimatsu A, Takahashi K, Hirane M, Fukushima N, Honoki K, Tsujiuchi T (September 2015). "Different roles of GPR120 and GPR40 in the acquisition of malignant properties in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 465 (3): 512–5. doi:10.1016/j.bbrc.2015.08.050. PMID26282200.
Takahashi K, Fukushima K, Onishi Y, Node Y, Inui K, Fukushima N, Honoki K, Tsujiuchi T (March 2017). "Different effects of G-protein-coupled receptor 120 (GPR120) and GPR40 on cell motile activity of highly migratory osteosarcoma cells". Biochemical and Biophysical Research Communications. 484 (3): 675–680. doi:10.1016/j.bbrc.2017.01.175. PMID28159555.
Zhang M, Qiu S (March 2019). "Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-κB signaling pathway". Anti-Cancer Drugs. 30 (3): 260–270. doi:10.1097/CAD.0000000000000716. PMID30520776. S2CID54568134.
Prado TP, Jara CP, Dias Bóbbo VC, Carraro RS, Sidarta-Oliveira D, de Mendonça GR, Velloso LA, Araújo EP (July 2023). "A Free Fatty Acid Synthetic Agonist Accelerates Wound Healing and Improves Scar Quality in Mice". Biological Research for Nursing. 25 (3): 353–366. doi:10.1177/10998004221142331. PMID36444640. S2CID254067558.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Karmokar PF, Moniri NH (December 2022). "Oncogenic signaling of the free-fatty acid receptors FFA1 and FFA4 in human breast carcinoma cells". Biochemical Pharmacology. 206: 115328. doi:10.1016/j.bcp.2022.115328. PMID36309079. S2CID253174629.
Duah M, Zhang K, Liang Y, Ayarick VA, Xu K, Pan B (February 2023). "Immune regulation of poly unsaturated fatty acids and free fatty acid receptor 4". The Journal of Nutritional Biochemistry. 112: 109222. doi:10.1016/j.jnutbio.2022.109222. PMID36402250. S2CID253652038.
Governa P, Caroleo MC, Carullo G, Aiello F, Cione E, Manetti F (June 2021). "FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity". Bioorganic & Medicinal Chemistry Letters. 41: 127969. doi:10.1016/j.bmcl.2021.127969. PMID33771587. S2CID232375863.
Li H, Liu Y, Xiao J, Huang J, Zhang Y (May 2023). "Preclinical pharmacokinetics and metabolism study of SCO-267, a GPR40 full agonist, in beagle dogs using ultra-high performance liquid chromatography coupled to tandem mass spectrometry". Biomedical Chromatography. 37 (9): e5685. doi:10.1002/bmc.5685. PMID37189222. S2CID258716947.
Teng D, Chen J, Li D, Wu Z, Li W, Tang Y, Liu G (June 2020). "Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators". Journal of Chemical Information and Modeling. 60 (6): 3214–3230. doi:10.1021/acs.jcim.0c00030. PMID32338509. S2CID216557375.
Wang B, Cai Z, Yao H, Jiao S, Chen S, Yang Z, Huang W, Ren Q, Cao Z, Chen Y, Zhang L, Li Z (January 2023). "Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes". European Journal of Medicinal Chemistry. 245 (Pt 1): 114883. doi:10.1016/j.ejmech.2022.114883. PMID36343410. S2CID253334545.
Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K (October 2011). "TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 228–37. doi:10.1124/jpet.111.183772. PMID21752941. S2CID14605410.
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (September 2016). "Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study". Diabetes, Obesity & Metabolism. 18 (9): 925–9. doi:10.1111/dom.12693. PMID27178047. S2CID21501077.
Iwasaki N, Sakamoto K, Kitajima S, Maruyama Y, Kuroda M (May 2021). "GPR120 agonists enhance the fatty orosensation when added to fat-containing system, but do not evoke it by themselves in humans". Physiology & Behavior. 234: 113383. doi:10.1016/j.physbeh.2021.113383. PMID33676959. S2CID232116893.
Sona C, Kumar A, Dogra S, Kumar BA, Umrao D, Yadav PN (October 2018). "Docosahexaenoic acid modulates brain-derived neurotrophic factor via GPR40 in the brain and alleviates diabesity-associated learning and memory deficits in mice". Neurobiology of Disease. 118: 94–107. doi:10.1016/j.nbd.2018.07.002. PMID29981843. S2CID51601327.
Khan MZ, Zhuang X, He L (May 2016). "GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model". Neurobiology of Learning and Memory. 131: 46–55. doi:10.1016/j.nlm.2016.03.006. PMID26976092. S2CID46877767.
Liu C, Cheng ZY, Xia QP, Hu YH, Wang C, He L (August 2021). "GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces β-amyloid production in APPswe/PS1dE9 mice". Psychopharmacology. 238 (8): 2133–2146. doi:10.1007/s00213-021-05837-4. PMID34173034. S2CID235648319.
Chen J, Li Q, Zhu J, Yuan Z, Wang T, Song J (December 2021). "GPR40 Agonist Ameliorate Pathological Neuroinflammation of Alzheimer's Disease via the Modulation of Gut Microbiota and Immune System, a Mini-Review". Neurotoxicity Research. 39 (6): 2175–2185. doi:10.1007/s12640-021-00408-z. PMID34505972. S2CID237472180.
Zhang M, Qiu S (March 2019). "Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-κB signaling pathway". Anti-Cancer Drugs. 30 (3): 260–270. doi:10.1097/CAD.0000000000000716. PMID30520776. S2CID54568134.
Prado TP, Jara CP, Dias Bóbbo VC, Carraro RS, Sidarta-Oliveira D, de Mendonça GR, Velloso LA, Araújo EP (July 2023). "A Free Fatty Acid Synthetic Agonist Accelerates Wound Healing and Improves Scar Quality in Mice". Biological Research for Nursing. 25 (3): 353–366. doi:10.1177/10998004221142331. PMID36444640. S2CID254067558.
